series-a
Stage
1
Investors
About
Ascidian Therapeutics develops RNA exon editing therapeutics that replace mutated human exons to restore normal protein production, targeting genetically defined diseases without altering DNA.
Explore Ascidian Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.